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ABSTRACT
Protein kinase C epsilon (PKCε) activation is a central mediator of the cardioprotection
conferred by myocardial ischemic preconditioning (IPC). PKCε activation via PKCε
peptide activator (PKCε+, HDAPIGYD) prior to ischemia is a pharmacologic mimic of
IPC. However, native PKCε+ requires the use of cell permeabilization methods, such as
conjugation to known carrier peptides, for effective intracellular targeting to mitigate
cardiac damage. Our study compares PKCε+ conjugated to either myristic acid (MyrPKCε+) or transactivating (TAT) carrier peptide (YGRKKRRQRRR-CC- PKCε+) with
native PKCε+ pretreatment and untreated control I/R hearts to evaluate the efficacy of
these cell permeable peptide analogs in attenuating contractile dysfunction and infarct
size after MI (30min)/R (90min). Infarct size was assessed by 1% triphenyltetrazolium
chloride staining of heart tissue, which was evaluated using NIH ImageJ software pixel
analysis and weight dissection analysis. ImageJ pixel analysis showed significantly
reduced infarct size in the Myr-PKCε+ (29±1%, p<0.05) and TAT-PKCε+ (25±2%,
p<0.01) pretreated hearts compared to native PKCε+ pretreated (34±2%) and control I/R
hearts (35±2%). By contrast, only TAT-PKCε+ pretreated hearts (26±2%, p<0.01)
exhibited significant difference from native PKCε+ pretreated hearts (35±2%) and
control hearts (36±2%) when evaluated via weight dissection. Despite significant
improvement in infarct size, there was no significant improvement in post-perfused
cardiac function across all groups. These results indicate that PKCε+ conjugation to
either Myr or TAT significantly improved its efficaciousness in attenuating infarct size
when given before ischemia. Further, this improvement was independent of cardiac

iv
function. These results suggest that Myr- or TAT-conjugated PKCε+ may be an effective
treatment to attenuate cell death in coronary bypass or organ transplantation settings.
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INTRODUCTION

1.1 Background
1.1.1 Preconditioning and protein kinase C
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for adults in
developed countries. Among these diseases myocardial infarction remains a major contributor to
the healthcare burden of CVD [1]. This damage is initiated by complete or partial blockage of a
coronary artery resulting in ischemia, a decrease in blood flow. Although timely reperfusion, or
restoration, of blood flow into the ischemic myocardium is necessary for survival, the rapid
restoration of physiological pH and generation of reactive oxygen species (ROS) by
dysfunctional mitochondria and uncoupled endothelial nitric oxide synthase (eNOS) results in
ischemic injury [2]. Attempts to reduce ischemic injury, characterized by irreversible
cardiomyocyte damage and compromised heart function, have provided insight into several
cardioprotective molecular mechanisms.
The cardioprotective effects of myocardial ischemic preconditioning (IPC), or brief nonlethal
intervals of ischemia followed by intermittent reperfusion, prior to prolonged ischemia have been
well established. IPC was first identified in 1986 by Murry et al. as an exogenous method to
delay cell death and reduce infarct size [3]. Myocardial IPC is characterized by several cycles of
brief ischemia (i.e. less than 4 min x3) followed by intermittent periods of reperfusion (i.e. less
than 6 min x3) prior to prolonged ischemia (i.e. greater than 30 min) [4]. This is an adaptive
response to protect the heart from the deleterious effects of prolonged ischemia during the final
reperfusion phase.
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Although initially poorly understood, over 20 years of research has identified diacyl glycerol
(DAG) or ROS mediated activation of protein kinase C epsilon (PKC) as a key effector
involved in preconditioning (Figure 1) [5]. PKC is an important enzymatic isoform of protein
kinase C (PKC) with paradoxical roles before and after prolonged ischemia. While PKC
inhibition is cardioprotective only at the time of reperfusion, PKC activation is cardioprotective
prior to prolonged ischemic insult and serves as a means to mimic preconditioning [6, 7]. PKC
is necessary and sufficient to increase cellular resistance to ischemic injury [8, 9]. The
observation that PKC-/- knockout mice do not benefit from IPC while cardiac-specific PKCε
overexpression confers cardioprotection similar to that of IPC have confirmed the central role of
PKC in preconditioning [8, 9].
The PKC family consists of several isoforms of Ser/Thr kinases with varying expression and
differential activation. All PKC isoforms are activated in a G protein-mediated (Gq) signaling
cascade resulting in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) and inositol
trisphosphate (IP3) to produce DAG and release Ca2+ from the endoplasmic reticulum,
respectively (Figure 1) [10]. While conventional PKC isoforms (cPKCs; , I, II, and )
require Ca2+ and DAG for activation, novel PKC isoforms (nPKCs; , , , and ) are activated
by DAG independently of Ca2+. Further, PKC atypical isoforms (nPKCs; / and ) are activated
by sphingomyelins (lipid rafts) and are DAG and Ca2+ independent [10]. All PKC isoforms are
variably expressed in many tissue of the body. In particular, PKC is constitutively expressed in
the heart, cerebellum, pancreas, ovaries, lungs, spleen, and adrenal glands (rats) [11]. Moreover,
PKC is highly expressed in human cardiac muscle and therefore suggests understanding this
mechanism would be of high value clinically in heart attack and organ transplant patients [12].

3

Within cardiomyocytes, inactive PKC is found in the cytosol and mitochondrial inner
membrane [13]. While PKC plays a role during cardiomyocyte differentiation and development,
its targets within the adult rat heart are the focus of this study [14]. There are more than 36
known targets of PKC. Of these PKC activation of eNOS and cardiac mitochondria are
putative targets for cardioprotection [13]. Regarding the mitochondria, basal levels of
mitochondrial PKC (mPKC) located in the inner mitochondrial membrane are augmented by
cytosolic PKC which translocates to the mitochondria following activation [13, 15]. PKC
import into the mitochondria is mediated by heat shock protein 90 (HSP90) and proceeds via a
mitochondrial import receptor, translocase of the outer membrane (Tom20) [16]. Whether
already located in the mitochondria or imported in, PKC phosphorylates mitochondrial KATP
channels (mitoKATP) which results in opening of mitoKATP. This mechanism is helpful for ATP
preservation and inhibition of mitochondrial permeability transition pore (MPTP) formation to
prevent rupturing of the mitochondria [17]. While PKC also translocates to cardiac sarcomeres
acting as a key mediator in maladaptive hypertrophy, sarcomeric KATP (sarcoKATP) channel
opening is not related to the cardioprotective mechanism of PKC in I/R injury [18, 19].
1.1.2 Sources of oxidative damage during I/R central to the preconditioning mechanism
The finding that diazoxide, an mitoKATP channel agonist, acts as a IPC mimetic while 5hydroxydecanoate (5-HD), an mitoKATP channel antagonist, eliminates preconditioning led to the
hypothesis that mitoKATP channels were involved in preconditioning [20]. A link between PKC
and mitoKATP channels was confirmed when it was found that PKC activation augments and
accelerates channel opening [21]. Further, the cardioprotective effects of mitoKATP channel
opening are blocked in the absence of PKC indicating that mitoKATP channels may be
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downstream of PKC [20]. However, the ROS released by opened mitoKATP channels directly
activate PKC through oxidation of its regulatory domain creating a positive feedback loop of
activation and channel opening [22].
A second part of the mitochondrial preconditioning signal transduction system is the MPTP.
This nonspecific pore spanning the inner and outer mitochondrial membranes opens during
reperfusion leading to mitochondrial swelling, uncoupling of oxidative phosphorylation, and
cytochrome c release. Unchecked mitochondrial permeability transition results in the collapse of
mitochondrial membrane potential and cell death [23]. PKC has been found to directly and
indirectly inhibit MPTP opening via phosphorylation of key pore components and mitoKATP
channel opening, respectively [24, 25]. Prevention of pore inhibition significantly attenuates the
cardioprotective effects of PKC, indicating that the MPTP plays at least a partial role in the
mechanism of PKC mediated preconditioning [25].
Although the full mechanisms by which mitoKATP channels and the MPTP are involved in
preconditioning have yet to be elucidated, PKC appears to be an essential effector. Costa and
Garlid proposed a unique mechanism of PKC induced cardioprotection effectively linking
mitochondrial inner membrane associated PKC with both mitoKATP channels and the MPTP.
Once the cardioprotective signaling pathway begins, activated cGMP-dependent protein kinase
(PKG) transmits the signal to the mitochondria via phosphorylation of an unknown
mitochondrial outer membrane protein (MOM). This signal is presumably transmitted to a first
pool of mitochondrial PKC (mPKC1) in the mitochondrial inner membrane resulting in
mitoKATP opening which in turn stimulates ROS release from complex I of the respiratory chain.
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The increase in ROS then activates a second pool of PKC (mPKC2) via oxidative modification
of its regulatory domain which then phosphorylates and inhibits the MPTP (Figure 1) [17].

Figure 1.

Schematic representation of PKCε activation and end effectors.

PKCε activation via DAG. ROS from dysfunctional mitochondria, and PKCε+ peptide activator. Activated PKCε then
phosphorylates mitochondrial KATP channels (mKATP) and mitochondrial transition permeability pore (MPTP).
Adapted from [17].

In addition to mitochondrial derived ROS, uncoupled eNOS is one of the major sources
of damaging ROS during reperfusion [26]. PKC is known to increase eNOS activity via
phosphorylation at ser1177 [27]. Regarding cardiac activation of endothelial derived NO release
in cardiac tissue, it has been shown that reducing NO release will decrease the coupling
efficiency of mitochondrial O2 consumption and ATP production, whereas increasing NO release
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improves the coupling efficiency of the electron transport chain to produce the same amount of
ATP with less O2 consumption [28]. Therefore there would be less mitochondrial derived ROS
produced from complexes I and III under conditions of NO synthesis which would occur prior to
prolonged ischemia where eNOS is in its coupled state. However, this mechanism may not be
helpful during reperfusion when the oxidation of eNOS cofactor tetrahydrobiopterin (BH4) leads
to dihydrobiopterin (BH2) production which competes with BH4 with equal affinity at the
oxygenase domain of eNOS. Under these conditions eNOS cannot produce NO and instead
produces superoxide which contributes to oxidative stress during reperfusion injury and
increases in hydrogen peroxide (H2O2) in tissues [28, 29].
1.1.3 PKC activator peptide
A pharmacological method by which to activate PKC is an isoform-specific PKC
activator peptide (PKC+), also known as RACK peptide (Figure 1). PKC function is known
to be mediated by anchoring proteins known as receptors for activated C kinase (RACK). Each
PKC isozyme has a RACK-selective recognition site distinct from its substrate binding site.
Activated PKC binds with high affinity to RACK, which translocates PKC to phosphorylate
substrates at specific intracellular sites to produce a physiologic response [30, 31, 32]. This study
utilizes several modifications of a well-established PKC+ peptide (HDAPIGYD), also known as
pseudo-RACK (RACK), as a chemical modality to mimic IPC [31]. Western blots and
immunofluorescence have confirmed PKC+-induced selective translocation of PKC from
cytosolic to particulate subcellular fractions which indicates PKC activation. In PKC+/+
overexpressed transgenic mice, PKC+ improved cardiac function and reduced levels of creatine
phosphokinase (CPK), a marker of cardiac damage in I/R hearts [33].
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Although the mechanism of action of PKC+ has yet to be elucidated, the predominant
theory states that PKC+ binds to inactive PKC rendering it active, or in an “open”
conformation that facilitates RACK binding [10]. This occurs via PKC+ binding to the
RACK binding site on PKC, effectively disrupting the auto-inhibitory intramolecular
interaction between its RACK-binding site and pseudo-RACK (RACK) binding site. This
interaction is due to PKC+ homology to amino acids 85-92 (HDAPIGYD) on the V1 domain of
PKC. The transient conformational opening induced by PKC+ is then stabilized by PKCRACK binding (Figure 2). This switch may be due to the partial homology between PKC+ and
RACK amino acids 285–292 (NNVALGYD) [32]. Once RACK is bound to PKC, PKC is
anchored in position to phosphorylate its intracellular targets.

Figure 2.

PKCε+ activates PKCε to facilitate RACK binding.

Proposed mechanism for PKCε activation by PKCε+ in which PKCε+ binds to the εRACK binding site to activate PKCε.
εRACK then binds to stabilize PKCε. Adapted from [32].
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However, unconjugated or native PKCε+ requires the use of cell permeabilization
methods (i.e., saponin treatment) for efficacious intracellular targeting to exert cardioprotective
effects [34]. This provides challenges in ex vivo and in vivo models where the integrity of the
organs must be maintained for analysis. Therefore, conjugating PKCε+ to known intracellular
delivery moieties may be a method to effectively activate PKCε for cardioprotection. Two
empirically successful modifications of PKC+ native peptide are myristic acid- (Myr) and
transactivating peptide- (TAT) conjugated PKC+ [6, 7].
TAT was originally an HIV-derived 86 amino acid peptide capable of penetrating the cell
membrane [35]. It has since been discovered that residues 49-57 of TAT (RKKRRQRRR) are
necessary and sufficient for internalization and serve as an efficient transduction domain [36].
The positively charged amino acid peptide presumably targets negatively charged proteoglycans
on the plasma membrane and enters the cell through endocytosis [37] (Figure 3). While the
complete mechanism by which TAT enters the cell has yet to be elucidated, there is evidence
that the basic arginine-rich peptide uses three endocytic pathways simultaneously:
macropinocytosis, clathrin-mediated endocytosis, and caveolar endocytosis [37]. Moreover, the
unique shape and bonding capabilities of the positively charged guanidinuim group on arginine
is essential in these endocytic processes [38]. Our study employs a undecapeptide conjugation
(YGRKKRRQRRR) from residues 47-57 of TAT with a reducible C terminus disulfide bond
(CC) to facilitate cargo release upon cellular internalization [39, 40]. Further, the hydrophilic
nature of this moiety provides great potential for therapeutic applications. [24, 25].
The TAT transduction domain has been widely used as a method to enhance cellular
uptake of PKC+ in MI/R experiments to mimic IPC. In cardiac myocytes, TAT-conjugated
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PKC+ showed selective PKC activation and translocation resulting in reduced adult cardiac
myocyte damage and increased cell viability after prolonged hypoxia [32]. In ex vivo models,
TAT-PKC+ pretretament has been shown to decrease CK release, improve left ventricular
developed pressure (LVDP), and reduce infarct size in Langendorff perfused rat hearts [7, 41].
The above studies used TAT-conjugated scrambled PKC+, native PKC+, and TAT alone as
controls, all of which had no cardioprotective effects [7, 32, 41]. In regards to in vivo
experiments, TAT-PKC+ administered via intraperitoneal (IP) injection showed PKC
translocation in the heart, brain, liver, lung, and kidney in mice. Further, no signs of systemic
toxicity were observed when TAT-PKC+ was administered once a day for 14 days [42].
Collectively, these results suggest that TAT is an effective cellular delivery moiety for PKC+.
By contrast, Myr is a lipophilic saturated fatty acid chain that enters the cell through
simple diffusion [43] (Figure 3). The attached cargo then enters the cell through simple diffusion
and is either released by an unknown cleavage mechanism or remains tethered to the fatty acid. It
is also possible that transbilayer exchange allows the myristoylated peptide to enter the cell
where it is targeted to other cellular membranes [44]. Although myristic acid-conjugated
peptides are less soluble than TAT-conjugated peptides in physiologic buffers, they provide an
efficacious mode of entry into various cell types due to their ability to enter the lipid bilayer
independently of any supplemental moieties [44, 45]. Additionally, Myr conjugated peptides
show rapid membrane association and homogenous distribution within cells which may provide
an advantage over the slower process of endocytosis and endosomal release [44].
The effective cellular uptake of myristoylated peptides has also been demonstrated in
several MI/R studies. In Langendorff perfused hearts, Myr-PKC+ pretreatment showed
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improved postreperfused LVDP and reduced polymorphonuclear leukocyte (PMN) infiltration
after MI(20min)/R(45min +PMNs) [6]. By contrast, when given at reperfusion, myristoylated
PKC peptide inhibitor (Myr-PKC-) showed reduction in infarct size and concentration
dependent improvement in postreperfused LVDP [46]. Additionally, an Myr-conjugated
mitochondrial fission inhibitor (Myr-P110) was effective in restoring of postreperfused cardiac
function and reducing infarct size in MI(30min)/R(90min) [47]. In toto, these results suggest that
Myr-conjugation facilitates the intracellular targeting of small peptides.

Figure 3.

Mode of entry for PKCε+

Native peptide (left), TAT-conjugated peptide (middle), and Myr-conjugated peptide (right). Native PKCε+
presumably enters via facilitated diffusion, TAT-conjugated PKCε+ enters via endocytosis, and Myr- PKCε+ enters
via simple diffusion.

While both moieties have been empirically proven to be effective in delivering cargo
sequences to interact with intracellular targets, there are a limited number of studies directly
comparing the effectiveness of cargo sequence delivery through these differing mechanisms in ex
vivo MI/R.
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1.2 Goal
Our study aims to use one MI(30min)/R(90min) model to directly compare the effects of native
PKC+, Myr-PKC+, and TAT-PKC+ pretreatment on cardiac contractile function and infarct
size. Further, we wanted to assess whether any differences between these moieties exist in
regards to infarct size reduction and restoration of postreperfused cardiac function.
1.2.1 Evaluating an extended reperfusion period for Myr-PKC+
Additionally, this study will evaluate whether cell permeable PKC+ would improve
postreperfused cardiac function within a longer reperfusion time period (i.e. 90 min) than a
previous study from our lab that used Myr-PKC+ in MI(30 min)/R(45 min) [48].
1.2.2 Examining inter-method reliability between pixel and weight based infarct measurement
Previous studies in our lab have isolated and weighed infarcted versus viable tissue to determine
infarct size (percent weight). While this method has been proven to be reliable, we wanted to
explore a method in which we could minimize researcher bias and create an image archive that
would allow for retrospective analysis. In this study, we began using NIH software ImageJ to
trace pixels of infarcted area versus viable tissue to determine infarct size (percent pixels). We
wanted to compare the reliability of using ImageJ pixel analysis to the previously used weight
dissection analysis [46, 48].
1.3 Hypothesis
We hypothesize that pretreatment with Myr-PKCε+ and TAT-PKCε+ will attenuate infarct
size using either percent weight or ImageJ pixel analysis, compared to native PKCε+ pretreated
and untreated control hearts in MI(30 min)/R(90 min). This comparison has great therapeutic
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value, as efficient intracellular drug delivery is central to improved histological and functional
outcomes in heart attack/coronary bypass patients and organ transplant recipients.
In regards to infarct size measurement technique, we predict that ImageJ pixel analysis will
yield potential for multiple and retrospective analyses to evaluate reproducibility of infarct size
measurement. However, we expect that weight- and pixel-based analyses will show similar intermethod reliability.

1

2

METHODS

2.1 Heart isolation & Langendorff heart preparation to examine contractile function
Male Sprague-Dawley rats (275-325g, Charles River, Springfield MA) were anesthetized
intraperitoneally with sodium pentobarbital (60 mg/kg) and anticoagulated with 1000
units heparin. The heart was then isolated from the rat and perfused through the
ascending aorta with oxygenated Krebs’ buffer (25mM NaHCO3, 17 mM dextrose, 5.9
mM KCl, 120 mM NaCl, 0.5 mM EDTA, 2.5 mM CaCl2, and 1.2 mM MgCl2)
maintained at 36.5°C as previously described [46]. The aorta was secured onto the
perfusion needle using surgical suture and was lowered into a reservoir filled with
warmed Krebs’ buffer. A constant pressure of 80mmHg, pH of 7.35-7.45, and a
temperature of 36.5°C was maintained throughout the experiment. Following a stable 15
minute equilibration period, hearts were pretreated with 5mL of buffer plus vehicle
(0.028% DMSO) for the control hearts or 5 mL of drug pretreatment (PKCε+, MyrPKCε+, TAT-PKCε+; 10M) dissolved in buffer at 1 mL/min infusion rate for 5 min
immediately prior to 30 minutes of global ischemia. After 30 minutes of ischemia, the
buffer flow was resumed for a 90-minute reperfusion period. A recording was taken
every 5 min throughout the experiment (baseline, pretreatment infusion, ischemia,
reperfusion) (Fig 3). Left ventricular end systolic pressure (LVESP), left ventricular end
diastolic pressure (LVEDP), heart rate, coronary flow, and maximum (+dP/dtmax) and
minimum (-dP/dtmin) rate of pressure change in the left ventricle were measured using a
microtip pressure catheter (SPR-524; Millar Instruments, Inc., Houston, TX) inserted into
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the left ventricle every 5 minutes throughout the equilibration, infusion, and reperfusion
period. LVDP was calculated as the difference between LVESP and LVEDP.

Pretreatment
.

Baseline

PKCε+, MyrPKCε+, or TATPKCε+ (10 M)

.

15 min

Global
ischemia

Reperfusion
.

90 min

30 min

.

5min
Figure 4.

Experimental protocol in the Langendorff perfused heart.

MI(30min)/R(90min)followed a 15 min equilibration period and 5 min infusion period.

2.1.1 Peptide formulations
Activator peptides Myr-PKCε+, TAT-PKCε+, and native PKCε+ were purchased from
Genemed Synthesis Inc., San Antonio TX. Native PKCε+ (HDAPIGYD) octapeptide is a
linear amino acid sequence. Myr is a saturated fatty acid, also known as 1-tetradecanoic
acid (CH3(CH2)12COOH), which was conjugated to the octapeptide PKCε+. TAT
(YGRKKRRQRRR) is conjugated to PKCε+ via a cysteine-cysteine double bond to
facilitate free cargo delivery (Table 1).
Table 1.
Peptide

PKCε activator peptide purity, sequence, and molecular weight.
Molecular weight
Purity (%)
Sequence
(g/mol)

Myr-PKCε+

>95%

CH3(CH2)12COOH-HDAPIGYD

1097

TAT-PKCε+

>95%

YGRKKRRQRRR-CC-HDAPIGYD

2632

Native PKCε+

>95%

HDAPIGYD

887
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2.1.2 Determination of drug concentration
10M final infusion concentration was chosen based on its ability to maximally stimulate
coupled eNOS activity as pretreatment therefore increasing NO release [6, 29]. Further,
the 10M concentration was used in previous studies in our lab assessing pretreatment
with Myr-PKC+ in an MI(30min)/R(45min) model [48].
2.1.3 Drug dose/preparation
100 L drug stock solutions were prepared for pretreatment infusion. Myr-PKCε+, TATPKCε+, and native PKCε+ (HDAPIGYD, MW= 887 g/mol) were solubilized separately
in 28% DMSO, 1% 1N HCl, and 71% diH2O. This drug preparation was based on the
empirically-determined minimum solubility requirements of the myristic acid-conjugated
peptide (Myr-PKC+). Drug stock was further solubilized in 5mL of Kreb’s buffer for
infusion and adjusted for coronary flow for a final 10 M drug concentration upon
infusion prior to global ischemia. Final vehicle concentration was 0.028% DMSO and
0.001% HCl.
2.1.4 MI/R hearts: Untreated control
Following a 15 minute equilibration period, 5mL of buffer containing 28 L DMSO, 1
L 1N HCl, and 71 L diH2O was infused into the heart, followed by 30 minutes of
global ischemia. The untreated MI/R control group allows one to analyze cardiac
function and infarct size data for hearts that are treated with and without PKCε+ peptides
and confirms negligible effect of vehicle on the heart.
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2.1.5 MI/R hearts: drug treated (PKCε+, Myr-PKCε+, TAT- PKCε+)
Drug treated hearts were subjected to the same I/R periods and conditions as untreated
control hearts with the exception of the 5 mL buffer pretreatment containing PKCε+,
Myr-PKCε+, or TAT- PKCε+ at a final concentration of 10 M in the perfusate.
2.1.6 Animal Care
Lab animals were from Charles River Laboratories Inc., Springfield MA. They were
12:12-h light:dark cycle and given 24 hour access to food and water. Male Sprague
Dawley rats were fed normal chow ad libitum and used for experiments at 275-325g. All
experiments were performed in accordance with the PCOM IACUC protocols A15-001
and A18-004.
2.2 Histological TTC staining to measure infarct size
After the 90 min reperfusion period, hearts were removed from the perfusion needle, and
frozen at -20°C for 30 minutes. The hearts were then dissected into 2 mm pieces in rat
heart slicer matrix with 2 mm transverse section slice intervals from apex to base and
stained with 1% Triphenyltetrazolium chloride (TTC) in Tris buffer (pH = 7.41) at 37°C
for 5 minutes. Viable tissue was stained red and necrotic tissue remained unstained.
Afterward, the tissue was fixed in 4% paraformaldehyde overnight to enhance contrast of
the stain.
2.2.1 ImageJ pixel analysis
For image analysis assessment, the infarcted area was calculated using NIH ImageJ
software. Heart sections were partially flattened between plexiglass slides with 2mm
spacers and photographed on both sides (superior and inferior). Infarcted area was traced
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to measure pixels on both the superior and inferior portions of each heart section and
averaged to get the infarcted pixel area of each section. Infarcted area was normalized to
the total pixel area of each heart. Multiple analyses of infarcted pixel area were
conducted for each experiment and calculated values were averaged.
2.2.2 Weight dissection analysis
For weight analysis assessment, sections viable and dead tissue were weighed (total). The
necrotic tissue was weighed and divided by the total weight to determine the infarct size
as previously described [22].
2.3 Statistical Analysis
All data in the figures are presented as means ± S.E.M. ANOVA analysis using StudentNeuman-Keuls test was used to assess statistical difference in infarct size and cardiac
function between untreated control I/R and PKCε+ I/R hearts. The same statistical
analysis was used to evaluate measurements of individual assessments by ImageJ pixel
analysis and weight analysis of TTC stained hearts. Probability values of < 0.05 were
considered statistically significant.

7

RESULTS
3.1 Examination of infarct size in response to PKC+ pretreatment
When assessed using NIH ImageJ software to determine percent of infarcted pixel
area compared to total pixel area of the heart after TTC staining, hearts pretreated with
Myr-PKC+ or TAT-PKC+ showed significant reduction in infarct size to 29±1%
(p<0.05, n=6) or 25±2% (p<0.01, n=6) respectively compared to untreated control
(35±2%, n=6) or native PKC+ pretreated I/R hearts (34±2%, n=6). By contrast, native
PKC+ pretreated I/R hearts did not show significant reduction in infarct size and
exhibited similar infarct size to that of untreated controls (Figure 5). This analysis was
done in a single-blind manner in which the treatment group was withheld from research
assistants analyzing the stained images of heart sections. Further, multiple researchers
were assigned to each experiment and their infarct analyses were averaged to determine a
mean infarct size for each experiment.
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Figure 5.

Percent pixel area infarct size.

Percent infarct size of Myr-PKCε+ (10 μM) I/R (red), TAT-PKCε+ (10 μM) I/R (yellow), native PKCε+ (10
μM) I/R (green), and untreated control I/R (blue) expressed as percent pixels of total heart pixel size using
NIH ImageJ software after TTC staining. Myr-PKCε+ and TAT-PKCε+ pretreatment significantly reduced
infarct size to 29±1% and 25±2% respectively compared to untreated control hearts, 35±2%. Myr-PKCε+
and TAT-PKCε+ pretreated hearts also showed significant reduction in infarct size compared to native
PKCε+. Native PKCε+ pretreated hearts showed similar infarct size to untreated controls and was not
significantly different, 34±2%. *p < 0.05 vs. untreated control I/R, ** p < 0.01 vs. untreated control I/R, #p
< 0.05 vs. native PKCε+, ##p < 0.01 vs. native PKCε+

When assessed by dissection to determine percent infarcted weight of total heart
weight after TTC staining, only TAT-PKC+ pretreatment significantly reduced infarct
size to 26±2% (p<0.01, n=6) compared to native PKC+ pretreatment and untreated
control I/R hearts which showed infarct size of 35±2% (n=6) and 36±2% (n=6)
respectively. Myr-PKCε+ pretreatment reduced infarct size to 30±2% (n=6), but this was
not significantly different from untreated controls. Native PKC+ pretreated hearts
showed similar infarct size to untreated control I/R hearts, 35±2% (n=6) and 36±2%
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(n=6) respectively (Figure 6). This analysis was not blinded and percent infarcted weight
was determined by only one researcher who performed the dissection 24 hours after each
experiment after heart sections had been photographed.

Figure 6.

Percent weight infarct size.

Percent infarct size of Myr-PKCε+ (10 μM) + I/R (red), TAT-PKCε+ (10 μM) + I/R (yellow), native PKCε+ (10
μM) + I/R (green), and untreated control I/R (blue) expressed as percent of total heart weight after TTC
staining. TAT-PKCε+ pretreatment significantly reduced infarct size to 26±2% compared to untreated
control and native PKCε+ hearts which exhibited a 36±2% and 35±2% reduction in infarct size respectively.
Myr-PKCε+ and native PKCε+ pretreatment did significantly reduce in infarct size, 30±2% and 35±2%
respectively, compared to untreated controls. ** p < 0.01 vs. untreated control I/R, ##p < 0.01 vs. native
PKCε+

3.2 Comparison of % pixel vs. % weight methods based on either total pixels or
total weight
To assess inter-method reliability between the pixel and weight based methods we
performed an ANOVA analysis using Student-Neuman-Keuls test. TAT-PKC+
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pretreated exhibited 25±2% (n=6; % pixels) and 26±1% (n=6; % weight) reduction in
infarct size and was significantly different from both untreated control and native PKC+
pretreated I/R hearts in both analyses (p<0.01). Similarly, Myr-PKCε+ pretreatment
reduced infarct size to 29±1% (n=6; % pixels) and 30±2% (n=6; % weight) but was only
determined to be significantly different from untreated control and native PKC+
pretreated I/R hearts in the ImageJ analysis of pixel area method (p<0.05). By contrast,
native PKC+ pretreated showed 34±2% (n=6; % pixels) and 35±2% (n=6; % weight)
infarct which was not significantly different from untreated controls, 35±2% (n=6; %
pixels) and 36±2% (n=6; % weight), using either method of infarct size analysis. In
general, the ImageJ analysis yielded slightly lower infarct size for all groups when
compared to the dissection analysis. Although these two methods presented slightly
different significance in results, they were not significantly different from each other
(Figure 7).
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Figure 7.

Comparison of infarct size analysis using dissection to determine percent infarct of
total weight and ImageJ to determine percent pixels of total pixel area.

Infarct size is shown as both percent weight (black) as determined by dissection and percent pixels (white)
measured using ImageJ. Myr-PKCε+ (10 μM) I/R, TAT-PKCε+ (10 μM) I/R, native PKCε+ (10 μM) I/R, and
untreated control I/R showed no significant difference within groups using either method.

3.3 Examination of cardiac performance in response to PKCε+ pretreatment
Despite differences in infarct size, there was no significant difference in +dP/dtmax,
-dP/dtmin, or LVDP across all groups tested (Table 2). Myr-PKCε+, TAT-PKCε+, native
PKCε+, and untreated control hearts restored post-reperfused LVDP to 35±7%, 40±9%,
32±5%, and 38±5% of baseline values respectively (Figure 8). Interestingly, MyrPKCε+ pretreatment exhibited significant improvement in post-reperfused LVEDP to
4910 mmHg (p<0.05, n=6) compared to TAT-PKCε+, native PKCε+, and untreated
control I/R hearts which restored LVEDP to 65±6 (n=6), 71±4 (n=6), and 71±4 mmHg
(n=6) respectively. Myr-PKCε+ pretreatment also exhibited significant reduction of
LVESP to 79±8 mmHg (p<0.05, n=6) compared to TAT-PKCε+, native PKCε+, and
untreated control hearts which restored LVESP to 99±4 (n=6), 101±2 (n=6), and 105±4
mmHg (n=6) respectively (Table 2). These differences in LVEDP and LVESP did not
result in a significant difference in LVDP (i.e., LVESP – LVEDP) because while LVEDP
was significantly lowered, LVESP was significantly raised compared to other groups.
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Table 2.

Cardiac function values for all groups.

Cardiac function initial (baseline) and final values for Myr-PKCε+ (10 μM) I/R (red), TAT-PKCε+ (10 μM) I/R
(yellow), native PKCε+ (10 μM) I/R (green), and untreated control I/R (blue) hearts. Myr-PKCε+
pretreatment exhibited significant improvement in post-reperfused LVEDP to 49±10 mmHg compared to
TAT-PKCε+, native PKCε+, and untreated control I/R hearts which restored LVESP to 65±6, 71±4, and 71±4
mmHg respectively. Myr-PKCε+ pretreatment also exhibited significant reduction of LVESP to 79±8 mmHg
compared to TAT-PKCε+, native PKCε+, and untreated control I/R hearts which restored LVESP to 99±4,
101±2, and 105±4 mmHg respectively. *p < 0.05 vs. untreated control I/R, TAT-PKCε+ I/R and PKCε+ I/R

Initial LVESP
(mmHg)
Initial LVEDP
(mmHg)
Initial LVDP
(mmHg)
Final LVESP
(mmHg)
Final LVEDP
(mmHg)
Final LVDP
(mmHg)
Initial +dP/dtmax
(mmHg/s)
Final dP/dtmax
(mmHg/s)
Initial dP/dtmin
(mmHg/s)
Final -dP/dtmin
(mmHg/s)
Initial Coronary
Flow (mL/min)
Final Coronary
Flow (mL/min)
Initial Heart
Rate (BPM)
Final Heart
Rate (BPM)

Myr-PKCε+
(10M) I/R (n=6)

TAT-PKCε+
(10M) I/R (n=6)

PKCε+
(10M) I/R
(n=6)

Control I/R
(n=6)

95.4 ± 2.8

92.7 ± 2.4

101.5 ± 5.4

97.9 ± 2.5

8.6 ± 0.8

8.4 ± 1.6

9.6 ± 2.9

9.9 ± 1.6

86.9 ± 2.6

84.3 ± 1.8

92.0 ± 3.5

88.0 ± 3.0

*79.4 ± 7.6

98.8 ± 3.9

100.4 ± 2.0

104.7 ± 3.6

*48.8 ± 9.8

64.9 ± 6.4

70.7 ± 4.3

71.3 ± 4.3

30.6 ± 5.8

33.9 ± 8.1

29.7 ± 4.9

33.4 ± 4.6

2335.1 ± 101.3

2083.3 ± 46.0

2176.1 ± 90.9

2287.5 ± 61.8

607.6 ± 135.9

694.8 ± 204.9

591.5 ± 85.0

743.2 ± 98.6

-1620.9 ± 88.0

-1375.7 ± 42.6

-1527.1 ± 67.2

-1557.7 ± 34.9

-403.4 ± 80.6

-517.6 ± 96.7

-501.8 ± 58.5

-484.1 ± 62.4

21.8 ± 1.3

20.5 ± 1.9

22.6 ± 2.0

21.0 ± 1.2

6.3 ± 0.6

6.6 ± 0.9

7.4 ± 1.1

6.5 ± 0.9

311.1 ± 16.2

284.0 ± 9.5

282.3 ± 10.2

294.0 ± 10.1

227.0 ± 20.9

245.8 ± 15.5

249.8 ± 15.5

249.1 ± 9.6
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Figure 8.

Initial and final LVDP values showed no difference across all groups.

Initial (black) and final (white) LVDP expressed in mmHg from isolated perfused rat hearts during stable
baseline recordings before pretreatment and ischemia (initial) and after 90 min reperfusion (final). MyrPKCε+, TAT-PKCε+, and native PKCε+ pretreatment I/R hearts recovered to 35±7%, 40±9%, and 32±5% of
baseline values respectively. No group exhibited a significant improvement in final LVDP compared to
untreated controls which recovered to 38±5% of baseline values.
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DISCUSSION

4.1 Summary of results
4.1.1 TAT-PKC+ and Myr-PKC+ attenuate infarct size
TAT-PKC+ pretreatment showed significant reduction in infarct size compared
to native PKC+ pretreatment and untreated control I/R hearts in both pixel and weight
analyses. Similarly, Myr-PKC+ pretreatment I/R hearts showed a significant reduction
in infarct size when assessed by pixels (29%) when compared to native PKC+
pretreatment and untreated control I/R hearts. However, the reduction in infarct size
conferred by Myr-PKC+ pretreatment was not significant in the weight analysis (30%).
These results indicate that PKC activation is cardioprotective before prolonged
ischemia. Moreover, native PKC+ did not significantly reduce infarct size (pixels=34%,
weight=35%) compared to untreated I/R controls by either mode of infarct analysis (see
Figures 5 and 6). Our results confirm that PKC+ (HDAPIGYD) requires a cell
permeable moiety for effective intracellular delivery and activation of PKC to attenuate
necrosis after prolonged ischemia. Further, TAT-conjugated PKCε+ may be superior to
Myr-PKC+ in reducing infarct size and facilitating PKCε preconditioning effects in
MI/R.
By contrast, Nelson et al. would suggest that Myr conjugation is more efficacious
than TAT conjugation for cargo sequence delivery, particularly in non-TAT permeant
lymphocyte derived cells. However, their study looked at a murine B lymphocyte cell
line (BA/F3) versus isolated organ preparations [44]. By comparison Patel et al. also

15
showed that Myr-conjugated Nox2 peptide inhibitor (Myr-peg gp91ds) was more
efficacious in reducing PMN superoxide release compared to TAT-gp91ds [49].
Regarding whole organ preparation, Benjamin et al. showed that Myr-P110, a
mitochondrial fission inhibitor, was more effective than TAT-P110 in restoring
postreperfused cardiac function and reducing infarct size [47]. It should be noted that
Benjamin et al. looked at specifically inhibiting a component of mitochondrial fission
which is more limited in its targets than the many targets (i.e., 36) of PKC [13]. It is
plausible to speculate that the Myr-P110 may have had better permeabilization and
efficient targeting due to the smaller size of P110 and being localized to one specific
target (Drp1/fis1 interaction) which is localized on the outer mitochondrial membrane
versus Myr-PKC+ which has many targets, which are not all localized to cellular
membranes.
In regards to the translocation mechanism of TAT, it is possible that processes
other than endocytosis contributed to rapid intracellular delivery. Interestingly, TerAvetisyan et al. showed TAT transduction into BHK21 (C-13) fibroblasts in clathrinmediated and caveolin-mediated endocytosis knock-outs as well as in fibroblasts
incubated at 4C. These results suggest that TAT is taken up into the cell in a process
independent of endocytosis, presumably through direct penetration of the plasma
membrane [50]. There are other reports showing that highly cationic peptides (R6-8) may
enter the cell through spontaneous translocation through the plasma membrane. However,
these studies require high peptide concentrations above a minimum threshold or
conditions in which strong membrane binding occurs [37]. Taken together, the multiple
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mechanisms by which TAT may enter the cell may have contributed to the efficient and
effective uptake of TAT-PKC+ in our experiments.
4.1.2 ImageJ pixel analysis versus dissection weight analysis of infarct size
Collectively, infarct size across all groups was slightly reduced when analyzed
using ImageJ compared to the weight dissection analysis, but this difference was not
significant. This may be attributed to the uneven distribution of infarcted area between
the superior and inferior side of each transverse myocardial cross-section. ImageJ pixel
area was calculated as the average of infarcted area on the superior and inferior portions
of each section. Interestingly, the ImageJ pixel analysis of infarct size more accurately
supports our working hypothesis that cell permeable conjugated PKC+ (i.e. Myr-PKC+
and TAT-PKC+) exhibited a greater reduction in infarct size than native PKC+ which
was no different than untreated control hearts. By contrast, the weight dissection analysis
of infarct size showed that only TAT-PKC+ pretreatment significantly reduced infarct
size when compared to native PKC+ and untreated control I/R hearts. In this regard, the
data from the weight based infarct analysis did not completely support our hypothesis.
Regardless, the results from this study would suggest that both methods are a reliable
way for which to measure infarct size after TTC staining since they did not differ from
each other. This supports our original hypothesis that both methods of measuring infarct
size show similar inter-method reliability (Figure 7).
One of the advantages of doing pixel reading is that images are archived and
multiple analyses of the data are possible in a single-blind manner. This allows for a
retrospective study analysis in which current data may be reanalyzed and compared to
other agents in future studies. By contrast, weight infarct analysis sometimes, but not
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always, entails a person who is familiar with the conditions of the experiment and is
therefore prone to researcher bias. Moreover, this method can only be performed one
time and, although it is designed that the same person will isolate the infarct versus viable
tissue, that is not always the case. As scientists try to do their best to be accurate, the fact
that we have limited people analyzing the weight method is limiting in itself and perhaps
could have contributed to the lack of significant reduction in infarct size after MyrPKC+ pretreatment versus the total blinded pixel based method (i.e., ImageJ). In
conclusion, the pixel method may be superior to the weight method because there is less
bias, there are more opportunities (i.e. number of people) to analyze the infarct area, it
allows for comparison across studies, and it is not time sensitive.
4.1.3 Cardiac Function
Despite reduction in infarct size, none of the PKC+ treated groups showed
significant recovery of cardiac function throughout the reperfusion period compared to
untreated control hearts. Interestingly, Myr-PKC+ pretreated exhibited significantly
improved LVEDP compared to TAT-PKC+, native PKC+, and untreated control
hearts, but this did not manifest in an improved LVDP due to significantly reduced
LVESP (see Table 2 and Figure 8). These results indicate that the infarct sparing effect of
pretreatment with PKC is independent of function recovery. These results are also
consistent with an earlier pilot study from our lab which showed that Myr-PKC+
reduced infarct size to 23% but did not restore cardiac function compared to untreated
controls using a similar ischemic time period (i.e. 30min) and a shorter reperfusion time
period (i.e. 45min) [48]. Our study was aimed at resolving whether cardiac function could
be restored at a longer reperfusion time modality. Our recently published work using

18
Myr-PKC peptide inhibitor (Myr-PKC-, 20 M) showed a delayed improvement in
cardiac function from 60 to 90 min [46]. This led us to explore the length of the
reperfusion timecourse in this study to see if there could be an improvement in cardiac
function that was not seen during the 45 min reperfusion period.
4.1.4 The dichotomy between infarct size and cardiac function
Interestingly, Saurin et al. reported no difference in LVDP in PKC-/- knockout
mice and mice with the full complement of PKC protein (PKC+/- heterozygous) in
MI(45 min)/R(90 min). Although PKC-/- mice were resistant to the cardioprotective
effects of IPC (i.e. infarct size reduction), postreperfused LVDP was preserved and
similar to that of IPC preconditioned PKC+/- mice [4]. Although PKC deficient mice
recovered LVDP, these results support our conclusion that the infarct sparing effects of
PKC may be independent of contractile recovery.
Myocardial stunning provides another possible explanation for lack of contractile
recovery despite reduction in infarct size. Kloner et. al showed that mitochondrial
directed antioxidant (SS-31) given at reperfusion reduced infarct size in three different
animal models. However, one of the animal models did not show restoration in cardiac
function despite showing reduction in infarct size [51]. Their explanation for this is that
the heart may have been stunned. Myocardial stunning is a phenomenon during which
asynchrony in the stunned myocardium impedes the ability of the organ to recover.
However, this contractile deficit is reversible as cardiomyocytes salvaged by reperfusion
are still viable [52]. It is quite plausible in this ischemia model that stunning could persist
throughout the timecourse in these experiments. It is also possible that diminished
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coronary flow at reperfusion leads to hibernation. This type of postischemic dysfunction
is defined as chronic depression of function and is thought to be an alternative protective
mechanism in which the heart responds to reduced O2 supply by downregulating cardiac
function and metabolism [53].
Nevertheless, reduction in infarct size is of great clinical relevance. Scar tissue,
measured by late gadolinium-enhanced (LGE) magnetic resonance imaging (MRI), has
been shown to be a better predictor of future events than contractile reserve in patients
with chronic MI [54]. In regards to acute MI, Wu et al. demonstrated that acute infarct
size relates to LV remodeling and is a better predictor of long-term prognosis than
cardiac function measurements (i.e. LV systolic performance) [55]. Therefore, infarct
size reduction via cell permeable PKC+ could improve the prognosis for patients who
suffer from chronic and acute myocardial infarction.
4.1.5 Length of ischemic period and recovery of cardiac function
Another rationale for the disparity between infarct size and cardiac function in our
experiments is the length of prolonged ischemia which plays a role in the extent to which
the heart may recover at reperfusion. Inagaki et. al showed recovery of cardiac function
when hearts were pretreated with TAT-PKC+ during MI(20min)/R(40min), but did not
report function data in their MI(40min)/R(120 min) model. It is plausible that the hearts
did not recover after the 40 min ischemic period even though there was still a reduction in
infarct size [7]. Teng et. al also used a MI(20min)/R(45min + PMNs) to simulate PMN
mediated I/R dysfunction to mimic in vivo conditions where PMN infiltration is
significant 3-4 hours post-reperfusion in regional MI/R injury [56, 57]. In this model,
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hearts pretreated with Myr-PKC+ (5M) exhibited improved postreperfused LVDP and
reduced PMN infiltration.
Taken together with our results in which cardiac function did not recover after 30
min of ischemia, it is plausible that 20 min of ischemia may not have been sufficient to
irreversibly depress contractile function before the end of the reperfusion period. By
contrast, going longer in ischemia (i.e., 30 min) cardiac function recovery was not
observed with either cell permeable moiety despite reduction in infarct size. Extending
the ischemic time period by 10 min may have caused prolonged myocardial stunning that
cell permeable PKC+ could not correct during the reperfusion time. Collectively, the
lack of function recovery after a longer ischemic time periods (i.e., > 30min) highlights
the importance of clinical timing of intervention (i.e. angioplasty) in patients with acute
myocardial infarction.
4.1.6 PKC before prolonged ischemia and at the onset of reperfusion
Various studies have demonstrated that PKC activation prior to prolonged
ischemia, and not at reperfusion, is cardioprotective. Inagaki et. al demonstrated that
TAT-PKC+ (500 nmol/L) decreased CPK release and improved LVEDP, LVDP, and
coronary vascular resistance (CVR) when administered prior to prolonged ischemia (i.e.
20 min) but not when administered at the onset of reperfusion in isolated perfused rat
hearts [7]. Along the same lines, Teng et. al observed that Myr-PKC+ (5 μM)
pretreatment restored postreperfused LVDP to 90±10% of baseline values in isolated
perfused rat hearts after 20 min ischemia with PMNs. This effect was not seen when
Myr-PKC+ was applied during reperfusion which restored LVDP to 75±7% of baseline
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values and was not significantly different from untreated control hearts [6]. We therefore
limited our study using PKC+ only as pretreatment to determine which cell permeable
moiety (i.e. TAT or Myr) provides more efficacious intracellular targeting.
Paradoxically, PKC inhibition by PKC- has been shown to be cardioprotective
when administered at the onset of reperfusion [6, 29, 46, 48]. In the same study in which
Myr-PKC+ was used, Teng et. al demonstrated that Myr-PKC- (5 μM) administered at
the onset of reperfusion significantly attenuated cardiac contractile dysfunction and PMN
adherence/infiltration after the 45 min reperfusion period [6]. In another study from our
lab, Myr-PKC- (5, 10, and 20 μM) given at reperfusion significantly reduced infarct size
and Myr-PKC- (10 and 20 μM) improved postreperfused LVDP during MI(30
min)/R(90 min) [46]. Although treatment at reperfusion may be more clinically relevant
during acute myocardial infarction, pretreatment may be valuable when the timing of the
ischemic event can be predicted such as during organ transplantation or coronary bypass.
4.2 Study Limitations
Although the Langendorff perfused heart provides a low cost, efficacious
screening method to study a wide range of compounds to mitigate reperfusion injury,
there are limitations. Organ isolation minimizes the number of confounding variables that
can effect in vivo studies in which organ systems are integrated. However, ex vivo studies
are less clinically relevant than in vivo studies. Although this preparation allows the study
of the heart over the course of several hours which was sufficient for our MI(30
min)/R(90 min) experiments, it would be advantageous to monitor the heart for a longer
period of time to determine if contractile function can be restored in the case of
myocardial stunning. Moreover, Sutherland and Hearse report that there is a 5-10%
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deterioration of contractile function per hour while being perfused in the Langendorff
model [58]. Regardless of the above limitations, the Langendorff perfused heart
preparation is highly reproducible, cost-effective, and well-suited to gain insightful data
in pilot studies.
4.3 Future Studies
4.3.1 PKC+ as pretreatment and PKC- at reperfusion
It would be interesting to explore the opposite roles of PKCε in MI/R by
pretreating hearts with cell permeable PKCε+ followed by PKCε- treatment at the onset
of reperfusion. Small amounts of protective ROS are necessary to initiate an adaptive
cardioprotective response before prolonged ischemia. PKC activation as a
preconditioning stimulus results in opening of mKATP channels and subsequent ROS
release, which in turn activates a second pool of PKC in the inner mitochondrial
membrane to phosphorylate and close the MPTP [17]. However, these cardioprotective
mechanisms are overwhelmed by increased ROS generation as a result of life-preserving
reperfusion. Therefore, PKC inhibition at reperfusion acts to inhibit uncoupled eNOS
and further mKATP channel opening which attenuates ROS release [29, 60]. We predict
PKCε activation as pretreatment and inhibition at reperfusion would have an additive
effect and may result in improved cardiac function and even lesser infarct size in the
Langendorff perfused heart.

23
4.3.2 Would promotion of eNOS coupling or eNOS uncoupling yield similar results to
20min ischemia model?
Perkins et. al demonstrated that promoting eNOS activity while simultaneously
promoting eNOS coupling via Myr-PKCε+ and BH4 respectively at reperfusion resulted
in increased NO release from rat femoral veins and improved postreperfused LVDP and
+dP/dtmax in Langendorff perfused hearts. By contrast, when Myr-PKCε+ was applied at
reperfusion to stimulate uncoupled eNOS activity in combination with BH2, there was
increased H2O2 endothelial release and cardiac function did not recover [29]. While
Perkins et. al evaluated the stimulation of coupled and uncoupled eNOS at reperfusion in
MI(20min)/R(45min + PMNs), it would be interesting to use PKCε+ in combination with
either BH4 or BH2 as pretreatment in MI(30 min)/R(90 min) to evaluate the role of
coupled versus uncoupled eNOS activity. We are interested in evaluating whether
promoting eNOS coupling before prolonged ischemia would still result in restoration of
postreperfused cardiac function in this longer I/R protocol. The reason that this may be of
value is that what we have recently learned from our research group that inhibiting
uncoupled eNOS via Myr-PKC- at reperfusion was still effective in MI(30 min)/R(90
min). However, the degree of restoration of postreperfused cardiac function was
diminished from ~100% seen after 20 min ischemia by Perkins et. al to ~56% after 30
min ischemia [29, 46].
While NO release from coupled eNOS improves the coupling efficiency of the
electron transport chain under normal conditions, it is possible that stimulation of
uncoupled eNOS prior to prolonged ischemia results in small amounts of protective ROS
[28]. Wang et. al found that sufficient concentrations of H2O2 pretreatment (i.e. 10-
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100M) are necessary to stimulate prosurvival pathways while low concentration H2O2
pretreatment (1M) further aggravated I/R injury during MI(30min)/R(45min) [59].
Therefore, PKC+ and BH2 induced stimulation of uncoupled eNOS and subsequent
superoxide release may propagate a protective signaling cascade which includes
downstream PKCε activation in the inner mitochondrial membrane to open mitoKATP and
prevent MPTP pore formation [17]. If this mechanism is helpful at longer ischemia times,
this may be helpful for organ transplantation.
4.3.3 Visualizing native PKC+, Myr-PKC+, and TAT-PKC+ within cardiomyocytes
In this study, efficacious intracellular targeting of PKC+ and subsequent PKC
activation yielding cardioprotection was extrapolated by measuring physiological
endpoints (i.e. contractile function and infarct size). Monitoring cargo translocation via a
well-designed cellular assay would confirm successful intracellular delivery of these
peptides and provide data on cellular distribution. Previous studies have used fluorescein
peptide conjugations and fluorescence microscopy to visualize mechanism of entry and
cellular distribution of cargo [44]. However, fluorescein would increase the size and
hydrophobic characteristic of these molecules which could influence mode of entry into
cells. Regardless, elucidating the mechanisms by which cell permeable peptides (i.e. Myr
and TAT) enter the cell are of value due to their great therapeutic potential.
In regards to successful PKC activation, a cellular assay measuring protein
expression of phosphorylated eNOS in human umbilical vein endothelial cells (HUVECs)
via western blot analysis could be used. HUVECs provide potential translation to human
tissue, and eNOS is a known PKC substrate which serves as principal ROS source in
MI/R [6, 29]. This is described as being a key mechanism in mediating reperfusion
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injury. Assessing differences in phosphorylated eNOS expression would be an effective
method to determine how well PKC+ is being delivered to cells and to assess potential
differences between Myr- and TAT-conjugated PKC+ delivery.
4.4 Significance of Findings
These results suggest that increasing cellular permeability of PKCε+ via
conjugation to either Myr or TAT significantly improved its efficaciousness in
attenuating infarct size when given prior to ischemia as a pharmacologic mimic of
ischemic preconditioning. The results also suggest that Myr- or TAT-conjugated PKCε+
may be an effective treatment to attenuate cell death in coronary bypass, angioplasty, or
organ transplantation settings.
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